73.54

1.55% 1.12

After Hours: 74.25 0.71 +0.97%

Intra Cellular Therapies Inc (ITCI)

Overview News Price History Option Chain Financials Discussions Forecast

Intra Cellular Therapies Inc stock is traded at $73.54, with a volume of 839.59K. It is up +1.55% in the last 24 hours and down -5.92% over the past month. Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Previous Close:

$72.42

Open:

$74.89

24h Volume:

839.59K

Relative Volume:

0.85

Market Cap:

$7.77B

Revenue:

$563.44M

Net Income/Loss:

$-84.30M

P/E Ratio:

-45.68

EPS:

-1.61

Net Cash Flow:

$-61.23M

1W Performance:

+0.35%

1M Performance:

-5.92%

6M Performance:

+11.37%

1Y Performance:

+27.98%

1-Day Range:

$73.02

$76.12

1-Week Range:

$71.75

$76.12

52-Week Range:

$45.50

$84.89

Intra Cellular Therapies Inc Stock (ITCI) Company Profile

Name

Intra Cellular Therapies Inc

Sector

Healthcare (1181)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

212-923-3344

Address

430 EAST 29TH STREET, NEW YORK, NY

Employee

561

Twitter

Next Earnings Date

2024-08-07

Latest SEC Filings

ITCI's Discussions on Twitter

Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-03-24	Initiated	Robert W. Baird	Outperform
Dec-11-23	Initiated	TD Cowen	Outperform
Apr-20-23	Initiated	Morgan Stanley	Overweight
Aug-22-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Jun-14-22	Initiated	UBS	Buy
Apr-22-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Initiated	Goldman	Buy
Sep-23-21	Initiated	Needham	Buy
Dec-15-20	Initiated	BofA Securities	Buy
Dec-10-20	Initiated	Goldman	Buy
Feb-20-20	Initiated	Evercore ISI	Outperform
Jan-31-20	Downgrade	JP Morgan	Overweight → Neutral
Dec-24-19	Reiterated	Canaccord Genuity	Buy
Aug-12-19	Initiated	Jefferies	Buy
Feb-26-18	Initiated	JP Morgan	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform
Dec-15-17	Initiated	Canaccord Genuity	Buy
Nov-08-17	Upgrade	SunTrust	Hold → Buy
Sep-07-17	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-30-17	Upgrade	Ladenburg Thalmann	Neutral → Buy
Aug-24-17	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Aug-23-17	Upgrade	Leerink Partners	Mkt Perform → Outperform
May-02-17	Downgrade	Ladenburg Thalmann	Buy → Neutral
May-02-17	Downgrade	Leerink Partners	Outperform → Mkt Perform
May-01-17	Downgrade	Piper Jaffray	Overweight → Neutral
Dec-16-16	Initiated	Cantor Fitzgerald	Overweight
Sep-29-16	Reiterated	RBC Capital Mkts	Outperform
Sep-29-16	Downgrade	SunTrust	Buy → Neutral

View All

Intra Cellular Therapies Inc Stock (ITCI) Latest News

Sep 06, 2024

Intra-Cellular Therapies (NASDAQ:ITCI) Lifted to Overweight at Piper Sandler - MarketBeat

Sep 06, 2024

Expert Ratings For Intra-Cellular Therapies - Benzinga

Sep 06, 2024

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report? - Yahoo Finance

Sep 06, 2024

Intra-Cellular Therapies (NASDAQ:ITCI) Shares Gap Up to $72.42 - MarketBeat

Sep 06, 2024

Sep 05, 2024

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Bank of New York Mellon Corp - MarketBeat

Sep 05, 2024